Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000232

Drug Information
NameGuanabenz
Synonyms5051-62-7; Hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)-; GBZ; NCGC00024846-03; Guanidine, [(2,6-dichlorobenzylidene)amino]-; CID5702063; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine; HMS2089G13; 2,6-Dichlorobenzylideneaminoguanidine; EINECS 225-750-8; C07034; Guanidine, ((2,6-dichlorobenzylidene)amino)- (8CI); NSC68982; NSC-68982; BRD-K67847053-015-08-8; LS-175166; Wy-8678; Wy 8678 base; Guanabenz [USAN:INN]; BSPBio_000052; N-((2,6-Dichlorobenzylidene)amino)guanidine; 23256-50-0 (monoacetate); Prestwick3_000096; Prestwick2_000096; N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; T6332738; LS-187161; CHEMBL420; NCGC00024846-04; Guanabenz monoacetate; AR-1J2045; Guanabenz acetate; [(2,6-Dichlorobenzylidene)amino]guanidine; Guanabenzo [INN-Spanish]; DB00629; C8H8Cl2N4; D04375; BR-750; ((2,6-Dichlorobenzylidene)amino)guanidine; Guanabenzum; CHEBI:101202; L000834; Hydrazinecarboximidamide, 2-[(2,6-dichlorophenyl)methylene]-; AC1NWAN0; Wytensin; NCGC00024846-05; AC1Q3P2X; Guanabenz (USAN/INN); Guanidine, ((2,6-dichlorobenzylidene)amino)-; Guanabenzo; MolPort-001-835-432; BPBio1_000058; NCGC00024846-02; guanabenz; Guanabenzum [INN-Latin]; 2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; Wy 8678; Guanabenz(USAN); Lopac0_000601
Trade NameWytensin
CompanyEon Labs Manufacturing
IndicationHigh blood pressure
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,
14)/b13-4+
InChIKeyWDZVGELJXXEGPV-YIXHJXPBSA-N
Canonical SMILESC1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl    
Isomeric SMILESC1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
Therapeutic ClassSympatholytics
CAS NumberCAS 5051-62-7
FormulaC8H8Cl2N4
PubChem Compound IDCID 5702063.
PubChem Substance IDSID 9246.
TargetAlpha-2 adrenergic receptorAgonist[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074149 To Reference
Ref 2Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543